Lynparza 50mg

Lynparza is indicated for the treatment in patients with advanced ovarian cancer Lynparza is indicated for the treatment in patients with HER2 – negative metastatic breast cancer.

Olaparib

Lynparza

50mg

Myriad genetic Laboratories




DESCRIPTION

Olaparib is generic form of brand name Lynparza
Olaparib belongs to type of oral poly (adenosine diphosphate–ribose) polymerase inhibitor which has promising antitumor action in patients with metastatic breast cancer and a germline BRCA mutation.
Lynparza is a prescription drug which used under the supervision of medical practioners

MECHANISM

Olaparib belongs to targeted therapy. Olaparib is a type of poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, contain PARP1, PARP2, and PARP3. PARP enzymes are included in DNA transcription, cell cycle managing, and DNA repair. Olaparib is aneffective oral PARP inhibitor which induces synthetic lethality in BRCA 1/2 deficient tumor cells via the formation of double-stranded DNA breaks which cannot be precisely repaired, which cause disruption of cellular homeostasis and cell death.



Pharmacokinetic

Maximum plasma concentration 1 to 3 hours %.

volume of distribution 167 +/-196 L, plasma protein binding is 82%

Primarily metabolised by CYP3A4

Excreted through the urine 44% and 42% through the feces. Half – life of Lynparza 11.9 hours




Blueberrypharma.com-img1

drug
Brand Lynparza
Ingredients Olaparib
Strength 50mg
Manufactured Myriad genetic Laboratories
Rating

DOSAGE AND ADMINISTRATION

Ovarian cancer:
Maintenance treatment of recurrent ovarian cancer
The tablet recommended dose is 300mg (two 150mg – mg tablets) PO BID
Continue treatment until disease progression or unacceptable toxicity
Monotherapy for advanced BRCA – mutated ovarian cancer :
Thetablet recommended dose is 300mg (two 150mg – mg tablets) PO BID
The capsules recommended dose is 400mg (eight 50mg- mg capsules) PO BID
Continue treatment until disease progression or unacceptable toxicity.
Maintenance treatment for advanced BRCA-mutated ovarian cancer :
The tablet recommended dose is 300mg (two 150mg – mg tablets) PO BID Follow the treatment until disease progression, undesirable toxicity o
r completion of 2 years of treatment
Finishing of 2 years of treatment:
• Patients with full response (no radiologic evidence): discontinue treatment
• Patients with indication of disease and may asset from continuous treatment: cure beyond 2 years.

SIDE EFFECTS

Common side effects :
• Decreased white blood cell count
• Abdominal pain
• Vomiting
• Upper respiratory tract infection
• Anemia
• Decreased neutrophils
• Musculoskeletal pain
• Diarrhea
• Decreased platelet count
• Decreased Haemoglobin
• Nausea
• Fatigue (including weakness)
• Increased serum creatinine
Less common side effects of patients administrating Olaparib :
• Myalgia
• Headache
• Skin rash
• Back pain
• Taste changes
• Cough
• Swelling
• Dizziness
• Constipation
• Urinary tract infection
• Heartburn
• Decreased appetite
• Shortness of breath.

SAFETY MEASURES

Lymphomas:
Haematological toxicity will cause in patients treated with Lynparza contain diagnoses or findings of generally mild or moderate anaemia, neutropenia, thrombocytopenia and lymphopenia.
When Lynparza monotherapy administrated to patient the incidence of myelodysplastic syndrome will occur.
On basis of mechanism of action (PARP inhibition), Lynparza could cause risk to fetal when administered to a pregnant woman.
Lynparza combination with strong or moderate CYP3A inhibitors is not recommended.

DRUG – DRUG INTERACTION

  • Interaction with myelosuppressive anticancer agents contains DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.
  • Concomitant use of strong CYP3A inhibitors (itraconazole, telithromycin, clarithromycin,) will increase Olaparib plasma concentration.
  • Concomitant use of strong CYP3A inducers (itraconazole, telithromycin, clarithromycin,) will decrease Olaparib plasma concentration.

Contraindications


None



Based on Lynparza mechanism of action, the drug causes risk to the fetal may occur when administrated to a pregnant woman.

No data available on the presence of Lynparza in human milk, hence avoid breast feeding during the treatment.

Store at 20°C - 25°C.

If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule. Consult doctors regarding missed dose.

Blueberrypharma.com-img2



Quick Contact




Prescription upload






PRESCRIPTION


Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.